Evidence map›Paper›PMID 38546841›Full record

ArticleEuropean journal of clinical pharmacology2024

Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.

Qian Dong, Chunli Chen, Max Taubert, Muhammad Bilal, Martina Kinzig, Fritz Sörgel, Oliver Scherf-Clavel, Uwe Fuhr, Charalambos Dokos

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Qian DongDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany. qdong2@smail.uni-koeln.de.
Chunli ChenDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Max TaubertDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Muhammad BilalDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Martina KinzigInstitute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
Fritz SörgelInstitute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
Oliver Scherf-ClavelDepartment Pharmazie, Ludwig-Maximilians-Universität München, Butenandtstr. 5, 81377, München, Germany.
Uwe FuhrDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Charalambos DokosDepartment I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
University Hospital Cologne · DEUniversity of Cologne · DEInstitute for Biomedical and Pharmaceutical Research · DELudwig-Maximilians-Universität München · DE

Funding

China Scholarship Council No. 202008320388the 2022 ESI International High Impact Research Article Cooperation Program No. 212-54900112the International Postdoctoral Exchange Fellowship Program from the Office of China Postdoctoral Council No. 2020106 and PC2020013the National Natural Science Foundation of Heilongjiang Province No. YQ2022C017
6 · The paper itself

Abstract

purposeAdefovir (as dipivoxil) was selected as a probe drug in a previous transporter cocktail phenotyping study to assess renal organic anion transporter 1 (OAT1), with renal clearance (CL

methodsData from 24 healthy subjects were reanalyzed. After establishing a base model, covariate effects, including the impact of co-administered drugs, were assessed using forward inclusion then backward elimination.

resultsA one-compartment model with first-order absorption (including lag time) and a combination of nonlinear renal and linear nonrenal elimination best described the data. A significantly higher apparent bioavailability (73.6% vs. 59.0%) and a lower apparent absorption rate constant (2.29 h

conclusionThe popPK modeling approach indicated that the co-administration primarily affected the apparent absorption and/or prodrug conversion of adefovir dipivoxil, resulting in the minor drug-drug interaction observed for adefovir as a victim. However, renal elimination remained unaffected. The high K

Indexed as

AdenineModels, BiologicalOrganophosphonatesAdultBiological AvailabilityDigoxinDrug InteractionsFemaleHumansMaleMetforminMiddle AgedOrganic Anion Transport Protein 1PhenotypeSitagliptin PhosphateYoung AdultadefovirAdenineDigoxinMetforminOrganic Anion Transport Protein 1OrganophosphonatesSitagliptin PhosphateAdefovirNonlinear renal eliminationOAT1-mediated drug-drug interactionsPopulation pharmacokinetics

Identifiers

PMID38546841
PMCPMC11156719
OpenAlexW4393272007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.